Moving up to 5mg Mounjaro: what the evidence says

What the SURMOUNT-1 trial tells us about early dose stages

The pivotal evidence for Mounjaro in weight management comes from the SURMOUNT-1 trial, published in the New England Journal of Medicine, which enrolled 2,539 adults with obesity across multiple dose arms. One of the consistent findings across the programme was that higher doses produced greater average weight reduction — participants on 15mg lost around 20–21% of body weight over 72 weeks, while lower maintenance doses produced more modest results. That dose-response relationship matters here, because it underpins why the 2.5mg opening dose is explicitly described in the SmPC as a tolerability measure rather than a treatment level. It exists to reduce the likelihood of nausea and GI upset when your body first encounters tirzepatide. Moving to 5mg is the first step where the medicine begins to work at a genuinely therapeutic level, and if you are weighing up that decision, our guide on whether to go up to 5mg Mounjaro walks through the key considerations in detail. That context is worth holding onto when you are wondering whether four weeks on 2.5mg is long enough before stepping up.

The licensed schedule, as set out in the Mounjaro prescribing information and summarised on the NHS medicines page for tirzepatide, describes titration roughly every four weeks. That four-week window is not arbitrary, it gives enough time to observe your GI tolerance at a given dose and for any initial side effects to settle before adding another step.

Signs your prescriber will look for before recommending 5mg

A prescriber considering whether you should move up to 5mg Mounjaro is not simply checking a date. They are looking at a few specific things. First, how did you tolerate 2.5mg? Persistent, significant nausea, vomiting or diarrhoea that has not settled by the end of week four can be a reason to stay at 2.5mg for longer before stepping up. Rushing an increase when GI side effects are still pronounced tends to compound them rather than resolve them. Second, has there been any early signal of response, reduced appetite, changes in portion size, a small shift in weight? These are reassuring signs that the medicine is working as expected, even at the starter dose. Third, your broader health picture: any kidney issues, gallbladder history, or other conditions that might influence the pace of titration will factor into the decision.

A practical checking habit that takes under a minute: at the end of each week on 2.5mg, note briefly in your phone whether you experienced nausea, vomiting or loose stools, and whether they are better, the same or worse than the previous week. That one-line log gives your prescriber far more to work with than a general impression. If you are thinking about going up a dose but are still getting meaningful GI symptoms in week four, raise that before any step-up rather than after.

What changes (and what to expect) once you reach 5mg

At 5mg, most patients begin to notice a more consistent reduction in appetite between injections. The dual GIP and GLP-1 receptor mechanism of tirzepatide means it acts on two pathways involved in hunger signalling and gastric emptying simultaneously, something worth understanding if you want to know why appetite suppression tends to deepen as the dose rises. Some people find that GI side effects return briefly when they move from 2.5mg to 5mg, in the same way they appeared at the very first injection. This is normal and usually resolves within one to two weeks, provided you are staying well hydrated and eating smaller, lower-fat meals. If you experience severe, persistent stomach pain that radiates to your back, seek medical attention promptly, this can, in rare cases, be a sign of pancreatitis, and the MHRA has highlighted acute pancreatitis as a known though infrequent risk with GLP-1 medicines.

For context on how 5mg fits into the broader treatment arc, the 5mg Mounjaro overview covers the dose in more detail, and you can also find specific information about the Mounjaro 10 mg/0.5 ml pen if you are thinking ahead to later stages of titration. And if you are already wondering about the next step, the question of moving up to 7.5mg follows the same clinical logic: tolerability first, evidence of response second, prescriber decision third.

The prescriber's role, and why dose changes are not self-managed

It is worth being direct about this. Mounjaro is a prescription-only medicine, and the titration schedule is not a self-service ladder. The reason dose changes require prescriber sign-off is not procedural, it is because the decision requires clinical judgement that accounts for your weight trajectory, any reported side effects, your other medicines (oral contraceptives, for instance, may have reduced absorption during the first four weeks of tirzepatide and after each dose increase, which is something to discuss explicitly), and any relevant health changes since your last review. NICE's guidance on tirzepatide, published as TA1026, also sets a review point if less than 5% weight loss has occurred after six months at the highest tolerated dose, reinforcing that the prescriber's ongoing involvement is part of the clinical framework, not just a regulatory formality.

At nume, every repeat order is reviewed by a GPhC-registered prescriber before it is dispensed, a real clinician reads your update, not an automated system. If you have questions about whether now is the right moment to step up, or you want a clinical view on how your 2.5mg period has gone, the straightforward route is to check your eligibility and speak to our prescribers. You can also read more about Mounjaro as a treatment or explore the broader weight-loss treatment options we offer if you are still deciding.